Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX

NCT05249101 is registered in ClinicalTrials.gov with CG Pharmaceuticals, Inc as lead sponsor.

NCT NCT05249101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX
Lead sponsor
CG Pharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 15, 2022
Completion date
July 31, 2026
Enrollment
70 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma